Categories Earnings, Health Care

Catalyst Pharmaceutical (CPRX): Q4 2019 Earnings Snapshot

— Catalyst Pharmaceutical (NASDAQ: CPRX) reported its fourth-quarter 2019 earnings of $0.07 per share versus $0.10 per share expected.

Earnings Update by AlphaStreet

— Total revenue soared to $30.12 million from $500 thousand a year ago. The analysts estimated revenue of $29.4 million for the fourth quarter.

— Selling, general and administrative expenses jumped by 65% year-over-year while research and development expenses fell by 25%.

— Looking ahead into fiscal 2020, the company still expects Firdapse net revenues to be in the range of $135-155 million.

— The company expects to report top-line results from the phase 3 trial for myasthenia gravis (MG) patients with autoantibodies to muscle-specific tyrosine kinase (MuSK) in the second quarter of 2020.

— Catalyst expects to report top-line results from the SMA Type 3 proof of concept trial in the second quarter of 2020. It predicts potential approval of New Drug Submission (NDS) for Firdapse to treat LEMS in Canada in the second half of 2020.

— Assuming the MuSK-MG trial is successful, the company hopes to submit a supplemental NDA for Firdapse for MuSK-MG around the end of 2020.

— In the face of the coronavirus Covid-19 outbreak, the company has been asked to provide a continuous uninterrupted supply of Firdapse. As of today, Catalyst has more than an adequate supply of Firdapse ready for shipment in the warehouse to meet patients’ needs through the end of this year.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

General Mills (GIS) Q4 Earnings: Key financials and quarterly highlights

General Mills Inc. (NYSE: GIS) reported fourth quarter 2022 earnings results today. Net sales increased 8% year-over-year to $4.9 billion. Organic net sales rose 13%. Net earnings attributable to General

KB Home (KBH): A look at the homebuilder’s expectations for the year

Shares of KB Home (NYSE: KBH) have dropped 35% year-to-date and 28% over the past 12 months. Last week, the company reported second quarter 2022 earnings results that surpassed expectations

Trade Desk’s stock can strengthen your investment portfolio. Here’s why

Trade Desk, Inc. (NASDAQ: TTD) has remained a much sought-after demand-side platform despite challenging market conditions and growing inflationary pressure, but its stock suffered heavy selling in recent months. The

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top